Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

Neurophet partners with Beijing LADO Technology… Intends to establish Joint Venture in China

* Neurophet enters into a strategic agreement with LADO to distribute Neurophet SCALE PET * Improves the efficiency of market entry with expertise of medical device go-to-market process inChina through the establishment of joint venture SEOUL, South Korea, Oct. 30, 2024 /PRNewswire/ -- Neurop...

2024-10-30 21:00 1418

Neurophet partners with Beijing LADO Technology… Intends to establish Joint Venture in China

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

- Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) onSaturday, November 9, 2024 ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the develop...

2024-10-30 19:00 973

World Stroke Congress | TASTE-2 significantly reduces stroke disability

NANJING, China, Oct. 30, 2024 /PRNewswire/ -- Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings regarding Sanbexin (edaravone and dexborneol concentrated solution for injection) has been published at the 16th World Stroke...

2024-10-30 15:36 1231

World Stroke Congress | TASTE-2 significantly reduces stroke disability

Pulsenmore Expands Partnership with Clalit Health Services to Deliver 25,000 Home Ultrasound Devices for Remote Prenatal Care

RAMAT GAN, Israel, Oct. 30, 2024 /PRNewswire/ -- Pulsenmore (TASE: PULS), a pioneering provider of home-based ultrasound technology, has announced the renewal and expansion of its strategic partnership with Clalit Health Services, Israel's largest HMO. Over the next five years, Pulsenmore will sup...

2024-10-30 14:00 994

Pulsenmore Expands Partnership with Clalit Health Services to Deliver 25,000 Home Ultrasound Devices for Remote Prenatal Care

Fosun Pharma Announces 2024Q3 Financial Results

Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- On October 29, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group";...

2024-10-30 10:41 1601

WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded the 2024 Global CRDMO Company of the Year Award by Frost & Sullivan, a gr...

2024-10-30 08:00 1165

Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA®  (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting

* Pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) previously demonstrated superior efficacy of subcutaneous (SC) infliximab over placebo for maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC)[1], [2] * ZYMFENTRA® is the first and only FDA-approved subcut...

2024-10-30 03:25 1206

DeepQure Presents Clinical Results of Laparoscopic RDN at TCT 2024, Demonstrating Cutting-edge Technology and Innovation

SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- DeepQure, a global pioneer in resistant hypertension treatment, has unveiled clinical results of its laparoscopic renal denervation (RDN) medical device "HyperQure". Designed to treat resistant hypertension,HyperQure uses a laparoscopic approach t...

2024-10-29 21:00 1445

Complete Genomics integrates NVIDIA Parabricks to offer researchers faster, more cost-effective and accurate genomic sequencing analysis

Complete Genomics DNBSEQ data and NVIDIA Parabricks yield deeper insights into genetic variants with deep learning SAN JOSE, Calif., Oct. 29, 2024 /PRNewswire/ -- Complete Genomics today announced an integration of its next-generation sequencing (NGS) DNBSEQ platforms* with NVIDIA Parabricks sof...

2024-10-29 21:00 1014

Qilian International Holding Group Limited Announces Name Change to BGM Group Ltd.

CHENGDU, China, Oct. 29, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ: BGM) is pleased to announce that effective onOctober 30, 2024, the Company will change its name to "BGM Group Ltd." In connection with the name change, the trading symbol of ...

2024-10-29 20:00 1813

GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement for Geographic Atrophy Therapies

YONGIN, South Korea, Oct. 28, 2024 /PRNewswire/ -- GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeutics, for the joint research and development of a novel treatment for geographic atrophy (GA...

2024-10-29 09:13 1644

KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I

Clinical Trials at American Society of Nephrology (ASN) – Kidney Week 2024 SAN FRANCISCO, Oct. 28, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to...

2024-10-29 05:42 983

Alimetry revolutionises gut health diagnosis by integrating AI into its wearable device, raises US $18m to fuel next phase of growth

MINNEAPOLIS, Oct. 28, 2024 /PRNewswire/ -- Alimetry has raised an oversubscribed US$18m A2 financing round to commercialise its wearable gut health monitoring device, capitalizing on increased adoption by a growing cohort of US hospitals. This adoption is driven by Alimetr...

2024-10-29 05:08 1084

$3M GRANT TO ACCELERATE DEVELOPMENT OF NEUROPLASTOGENS FOR SUBSTANCE USE DISORDER TREATMENT

CRC-P GRANT SECURED BY TESSARA THERAPEUTICS, PSYLO, AND THE UNIVERSITY OF SYDNEY TO ADVANCE BRAIN-REWIRING TREATMENTS FOR ADDICTION BOULDER, Colo. , Oct. 28, 2024 /PRNewswire/ -- Tessara Therapeutics , Psylo , and the...

2024-10-29 02:00 1431

Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY

* Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year * Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-19 Commercial Projects, Up 4.6% Year-over-Year * Net Profit Attributable to the Owners o...

2024-10-28 19:03 1848

I-Mab to Participate at the Truist Securities BioPharma Symposium

ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meet...

2024-10-28 19:00 893

WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development

SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expressio...

2024-10-28 17:00 1006

RiboX Therapeutics Announces FDA Clearance for IND Application of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation

PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, announced that the US Food and Drug Administration (FDA) has cleared its IND application for th...

2024-10-26 01:24 3906

KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD)

SAN FRANCISCO, Oct. 25, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the U.S. Fo...

2024-10-26 00:33 1670

WOORIEN launches 'MyVet CT Plus': Advanced Veterinary imaging Solution

* Lowering CT barriers and improving diagnostic quality * Spiral-Linear Technology with Enhanced Power * Various and Wide FOV with Reduced Scan Time HWASEONG, South Korea, Oct. 25, 2024 /PRNewswire/ -- WOORIEN Co., Ltd, a company specializing in veterinary imaging equipment and solutions, pr...

2024-10-25 21:00 2426

WOORIEN launches 'MyVet CT Plus': Advanced Veterinary imaging Solution

1 2 345 6 7 ... 213